Showing results (611-620 of 1,837) with videos related to

Sort By:
Pageof 184
ESMO Open|August 2, 2017
S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT studyHideo Baba, Yasuhide Yamada, Daisuke Takahari, et al.
ESMO Open|August 2, 2017
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimateAnne Hansen Ree, Hege G Russnes, Daniel Heinrich, et al.
ESMO Open|August 2, 2017
New treatment options for metastatic renal cell carcinomaAlejo Rodriguez-Vida, Thomas E Hutson, Joaquim Bellmunt, et al.
ESMO Open|August 2, 2017
European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancerStefan Cristian Stanel, Jan Sjöberg, Tomas Salmonson, et al.
ESMO Open|December 7, 2017
Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?Matthew C Cheung, Kelvin K W Chan, Mona Sabharwal, et al.
ESMO Open|December 7, 2017
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancerFiona Blackhall, D Ross Camidge, Alice T Shaw, et al.
ESMO Open|November 28, 2017
Targeting immune checkpoints in breast cancer: an update of early resultsCinzia Solinas, Andrea Gombos, Sofiya Latifyan, et al.
ESMO Open|November 25, 2020
Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumoursEmilie Le Rhun, Michael Weller
ESMO Open|September 5, 2020
How I treat anal squamous cell carcinomaGiulia Martini, Gianluca Arrichiello, Carola Borrelli, et al.
ESMO Open|November 5, 2020
Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patientsAdam Pluzanski, Maciej Krzakowski, Dariusz Kowalski, et al.
Pageof 184